Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England. Leon Neal | Getty Images News | Getty Images Once the go-to location for global drugmakers, Europe is now being squeezed by President Donald Trump’s aggressive trade and drug-pricing…
Revolution Medicines could be on the cusp of a breakthrough. The company expects to soon release results from a Phase 3 trial of its experimental drug that could become the first targeted treatment for pancreatic cancer, the deadliest of the major cancers. Just 13% of people with pancreatic cancer live five years after they’re diagnosed,…
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.” Zuckerman, a 32-year-old data analyst based in Washington, D.C., said she lost 90 pounds in college and spent years cycling through nutritionists, therapy and strict routines — only to find herself at her heaviest…
Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks during an event sponsored by the Action for Progress Coalition, at the National Press Club in Washington, D.C., U.S., Feb. 2, 2026. Al Drago | Reuters The Trump administration on Monday finalized a 2027 payment rate increase to privately run Medicare plans that…
The Trump administration on Thursday imposed new tariffs on branded drugs from pharmaceutical companies that have not struck deals with the president to lower their U.S. drug prices – a long-awaited move that will likely only affect a small portion of drugmakers. “We need to make sure that our drug supply is protected, secure and…
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake | Reuters BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. The agreement will give Insilico…
Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of Every Cure A version of this story first appeared in the CNBC Cures newsletter. Click here to sign up. There are over 10,000 rare diseases — 95% of which don’t have a cure. It can cost billions…
Abivax is planning to raise money after releasing key trial data in June, its CEO told CNBC on Tuesday, signaling to potential buyers of the firm that it is in no rush to sell. Intense takeover rumors have surrounded the French biotech company for months, impacting the volatile stock that rose nearly 1,700% in 2025….
Always products are displayed on a shelf in a supermarket in Sarajevo, Bosnia and Herzegovina October 29, 2024. Dado Ruvic | Reuters Rising inflation and ever-changing tariff policies have led to higher prices across store shelves over the past few years, squeezing consumers’ budgets. An often overlooked example: menstrual products. The average price of menstrual…
Last summer, my sister Becky approached me with an idea. She wanted my help building a platform at CNBC to spotlight the 30 million Americans living with a rare disease. Becky hoped that doing so would help give a voice to the millions of people that are often overlooked by the medical community … who…
